Here are 1-3 brief analogies to describe CRISPR Therapeutics:

• CRISPR Therapeutics is like a Moderna for gene editing, pioneering a revolutionary new platform technology (CRISPR) to develop medicines for serious diseases.
• CRISPR Therapeutics is like a Vertex Pharmaceuticals for a broader range of genetic diseases, developing breakthrough treatments by directly addressing the underlying genetic causes.

• CTX001: An ex vivo CRISPR gene-edited therapy for treating transfusion-dependent beta-thalassemia or severe sickle cell disease.
• CTX110: A donor-derived gene-edited allogeneic CAR-T investigational therapy targeting CD19 positive malignancies.
• CTX120: A donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for relapsed or refractory multiple myeloma.
• CTX130: A donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 for various solid tumors and hematologic malignancies.
• VCTX210: A gene-edited immune-evasive stem cell-derived product candidate for the treatment of Type 1 Diabetes.
• In vivo gene-editing programs: Therapeutic programs targeting diseases in the liver, lung, muscle, and central nervous system.

CRISPR Therapeutics (CRSP) sells primarily to other companies through strategic partnerships for the development and potential commercialization of its gene-editing therapies. Its major customers/partners include:

• Bayer Healthcare LLC (part of Bayer AG, symbol: BAYN)
• Vertex Pharmaceuticals Incorporated (symbol: VRTX)
• Nkarta, Inc. (symbol: NKTR)

Samarth Kulkarni, Ph.D. Chief Executive Officer and Chairman of the Board
Samarth Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics since 2017 and became Chairman of the Board in September 2023. He joined CRISPR Therapeutics in 2015 as Chief Business Officer during the company's early stages, where he played a key role in developing its strategy and forging initial partnerships with biopharma companies like Vertex and Bayer. Under his leadership, CRISPR Therapeutics developed the world's first approved gene-edited treatment for sickle cell disease and transfusion-dependent beta-thalassemia. Before joining CRISPR, Dr. Kulkarni was a Partner at McKinsey & Company, where he held a leading role in the Pharmaceutical and Medical products practice and co-led the biotech practice, focusing on strategy and operations. He serves on the Board of Directors of Black Diamond Therapeutics, Centessa Pharmaceuticals, Repare Therapeutics, and Oruka Therapeutics. Dr. Kulkarni holds a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology.

Raju Prasad, Ph.D. Chief Financial Officer and Principal Accounting Officer
Raju Prasad has served as the Chief Financial Officer of CRISPR Therapeutics since March 14, 2023. Prior to joining the company, he was a Partner and senior biotechnology analyst at William Blair & Company from March 2014 to March 2023, where he led the firm's initiative on covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad's previous experience includes working as a research associate with the University of North Carolina at Chapel Hill's Gillings School of Global Public Health and as an independent consultant with the U.S. Environmental Protection Agency. He also serves on the advisory board of Portal Innovations, a life sciences venture development engine. Dr. Prasad holds a B.A. in cell biology and neuroscience from Rutgers University, an M.S. in exercise physiology from the University of Delaware, and a Ph.D. in environmental sciences and engineering from the University of North Carolina at Chapel Hill. He is the author of "Building Breakthroughs: On the Frontier of Medical Innovation".

James R. Kasinger General Counsel and Head of Legal
James R. Kasinger serves as the General Counsel and Head of Legal at CRISPR Therapeutics. He joined the company in 2017, bringing extensive experience in the biotechnology sector. Prior to CRISPR Therapeutics, he was Vice President, General Counsel, and Secretary at Editas Medicine. His career also includes roles at Intralytix, Inc., Genzyme Corporation, and as a partner at the law firm of Palmer & Dodge LLP. Mr. Kasinger holds a J.D. from Georgetown University Law Center and a B.A. from Dartmouth College.

Stephen Kennedy Chief Commercial Officer
Stephen Kennedy is the Chief Commercial Officer at CRISPR Therapeutics. He joined the company in 2021, bringing over 25 years of experience in the pharmaceutical and biotechnology industries. Before joining CRISPR Therapeutics, Mr. Kennedy was the Chief Commercial Officer at Sage Therapeutics. His background includes significant commercial leadership roles at Biogen, where he contributed to the launch and growth of several key therapies across various therapeutic areas. He earned an M.B.A. from the Kelley School of Business at Indiana University and a B.S. in Marketing from the University of Massachusetts Dartmouth.

Megan Wherry Menner Chief Human Resources Officer
Megan Wherry Menner is the Chief Human Resources Officer at CRISPR Therapeutics. She joined the company in 2021. Prior to her role at CRISPR Therapeutics, she served as Vice President, Head of Human Resources at Sarepta Therapeutics. Her experience spans various human resources leadership positions in global biopharmaceutical companies, including Sanofi Genzyme, where she supported multiple functions including R&D, commercial, and manufacturing. Ms. Menner holds an M.B.A. from the Boston College Carroll School of Management and a B.A. in Psychology from the University of Notre Dame.

1. Clinical Development, Regulatory, and Commercialization Risk: The primary risk for CRISPR Therapeutics stems from the extensive and often unpredictable process of developing and commercializing its gene-editing therapies. Despite the historic approval of Casgevy (exa-cel) for sickle cell disease and beta-thalassemia in partnership with Vertex Pharmaceuticals, the company's future success heavily relies on the successful advancement, regulatory approval, and market adoption of its broad pipeline, including other hemoglobinopathy programs, oncology (CAR-T therapies like CTX110, CTX120, CTX130), regenerative medicine (VCTX210 for type 1 diabetes), and various in vivo gene-editing programs. Clinical trials are inherently uncertain, and failures, setbacks, or significant delays in any of these programs could substantially harm the company's financial health and prospects. For instance, while Casgevy has received approvals, its rollout has faced logistical challenges and high treatment costs, leading to ongoing net losses for CRISPR Therapeutics.
2. Intellectual Property and Patent Disputes: The foundational technology of CRISPR Therapeutics is its proprietary CRISPR/Cas9 platform. The gene-editing field is characterized by a complex and highly litigious intellectual property landscape, with ongoing disputes over the ownership of foundational CRISPR/Cas9 patents. While the company has a strong patent portfolio, adverse outcomes in these disputes or the need to secure costly licenses from other patent holders could significantly impact its ability to develop and commercialize its therapies without infringement. The evolving nature of these legal battles creates uncertainty and can incur substantial legal costs, potentially delaying therapeutic pipelines.
3. Intense Competition and Potential for Technological Obsolescence: CRISPR Therapeutics operates in a rapidly evolving and highly competitive environment. Numerous other biotechnology and pharmaceutical companies are also developing gene-editing and gene therapy technologies, including those utilizing CRISPR/Cas9, as well as next-generation platforms like base or prime editing. This competition spans various disease areas targeted by CRISPR Therapeutics, such as hemoglobinopathies, oncology, and rare diseases. The emergence of superior, safer, or more cost-effective gene-editing technologies or alternative treatments from competitors could potentially diminish the competitive advantage of CRISPR Therapeutics' platform and product candidates, or even render them obsolete. Additionally, there are ongoing scientific concerns and studies regarding potential off-target effects or safety risks (e.g., increased risk of cancer) associated with CRISPR/Cas9 gene editing, which could affect regulatory perception and public acceptance, thereby impacting all companies relying on this technology.

The emergence and continued development of **next-generation gene editing technologies, such as base editing and prime editing**, represent an emerging threat. Companies like Beam Therapeutics (focusing on base editing) and Prime Medicine (focusing on prime editing) are actively advancing these platforms, with some programs already in clinical development. These technologies aim to achieve precise genetic changes without creating double-strand DNA breaks, which could potentially offer advantages in terms of safety (e.g., fewer off-target effects, reduced chromosomal translocations) and precision compared to CRISPR/Cas9. If these alternative gene editing platforms demonstrate superior safety profiles, enhanced efficacy, or broader applicability across various therapeutic areas, especially for in vivo applications, they could gradually challenge the long-term competitive advantage of CRISPR Therapeutics' proprietary CRISPR/Cas9 platform and potentially displace it for certain indications.

Expected Drivers of Future Revenue Growth for CRISPR Therapeutics (CRSP) over the Next 2-3 Years:

• Continued Commercialization and Market Expansion of CASGEVY (exa-cel): CRISPR Therapeutics expects significant revenue growth from the increasing global adoption and expanded access of CASGEVY, its gene-editing therapy for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company, in partnership with Vertex Pharmaceuticals, is seeing continued momentum with patient initiations and cell collections, which nearly tripled in 2025 compared to 2024. Furthermore, regulatory submissions for CASGEVY in pediatric patients (ages 5-11) for SCD and TDT are anticipated in the first half of 2026, which would broaden the eligible patient population and further drive sales. Analysts project substantial revenue increases for CRSP, attributing this growth to increased patient starts and an expanding patient funnel for CASGEVY.
• Advancement and Potential Commercialization of Key Pipeline Programs: Beyond CASGEVY, CRISPR Therapeutics has a robust pipeline with several promising candidates that are expected to be significant revenue drivers. This includes CTX611 (SRSD107), a long-acting siRNA therapy targeting Factor XI for the prevention of thromboembolic disorders, which is in Phase 2 clinical trials with top-line data expected in the second half of 2026 and could tap into a multi-billion-dollar global market. Additionally, zugo-cel (formerly CTX112), an allogeneic CAR-T investigational therapy for B-cell malignancies and autoimmune diseases, is anticipated to provide updates in the second half of 2026, potentially opening new revenue streams. Other in vivo gene-editing programs, such as CTX310 for severe hypertriglyceridemia and refractory hypercholesterolemia, and CTX460 for alpha-1 antitrypsin deficiency (AATD), are also progressing through clinical development, with planned clinical trial initiations and data updates in mid to late 2026, contributing to future growth.
• Revenue from Strategic Partnerships and Collaborations: A crucial component of CRISPR Therapeutics' future revenue growth stems from its strategic collaborations. The established partnership with Vertex Pharmaceuticals for CASGEVY is a primary example, generating significant revenue for the company through shared profits. Beyond this, collaborations such as the one with Sirius Therapeutics for siRNA-based programs, including SRSD107, and the agreement with Lilly for zugo-cel in aggressive B-cell lymphomas, are expected to contribute to revenue through milestone payments, cost-sharing, and potential royalties as these programs advance and achieve commercial success. These partnerships provide both financial support for ongoing research and development and a pathway to bring new gene-edited therapies to market, diversifying revenue sources.

Share Repurchases

Share Issuance

• In March 2026, CRISPR Therapeutics priced an upsized private offering of $550 million in convertible senior notes due 2031, with an option for initial purchasers to acquire an additional $50 million. The estimated net proceeds are approximately $536.3 million, or $585.2 million if the option is fully purchased.
• CRISPR Therapeutics secured a notable financing boost in the third and fourth quarters of 2025, with net cash from continuing financing activities reported at +$296.8 million in Q3 2025 and +$116.4 million in Q4 2025.
• As part of an expanded collaboration agreement in April 2021, Vertex Pharmaceuticals made a $30 million equity investment in CRISPR Therapeutics.

Inbound Investments

• In April 2021, Vertex Pharmaceuticals expanded its collaboration with CRISPR Therapeutics, making an upfront payment of $900 million.
• Under the amended agreement for CTX001 (now CASGEVY), Vertex assumed lead responsibility for global development, manufacturing, and commercialization, covering 60% of program costs and receiving 60% of profits from future worldwide sales. This also included a potential for an additional $200 million upon the first regulatory approval.

Outbound Investments

Capital Expenditures

• CRISPR Therapeutics reported capital expenditures of $0.91 million in 2025, $1.90 million in 2024, and $9.47 million in 2023.
• For the fourth quarter of 2025, capital expenditures amounted to $517K.
• The estimated net proceeds from the March 2026 convertible notes offering are designated for general corporate purposes, which include funding the company's pipeline and commercialization efforts for its gene-editing therapies.